Design and development of transdermal drug delivery systems of metoprolol succinate

Abstract

Introduction: Most of the drugs taken orally are found to be not as effective as desired. To overcome such problems transdermal drug delivery system has been developed. Transdermal drug delivery systems (TDDS) are dosage forms which involve in the drug transport to viable epidermal and or dermal tissues of the skin for local therapeutic effect while a very major fraction of drug is transported into the systemic blood circulation. Several important advantages of transdermal drug delivery are limitation of hepatic first pass metabolism, enhancement of therapeutic efficacy and maintenance of steady plasma level of the drug. Materials and Methods: The current research work includes the development of Metoprolol succinate transdermal patches and their evaluation. The transdermal patches were formulated by solvent casting method varying the concentrations of Eudragit NE 30D (%v/w) and DMSO (%w/w of dry polymer). Results: Among the nine formulations of the transdermal patches F3 formulation was considered as the optimized formulation considering its tensile strength, percentage elongation, percentage drug content and mainly cumulative percentage drug diffusion. The cumulative percentage drug diffused from F3 formulation was found to be 97.36 at the end of 24th hour. Conclusion: Stable and effective transdermal drug delivery systems of metoprolol succinate for once daily administration were prepared for better patient compliance. Keywords: Transdermal drug delivery, Solvent casting method, Metoprolol succinate, Ttherapeutic efficacy, Steady plasma level.